Digital Content 
NEWS #PharmaBuzz
24 Jun 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250624605890/en/Nuvation-Bio-Announces-National-Comprehensive-Cancer-Network-Adds-Taletrectinib-IBTROZI-as-Preferred-Option-to-Clinical-Practice-Guidelines-in-Oncology-for-Advanced-ROS1-Non-Small-Cell-Lung-Cancers
16 Jun 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/06/16/3099726/0/en/Onco360-Has-Been-Selected-as-a-National-Specialty-Pharmacy-Partner-for-IBTROZI-taletrectinib-Manufactured-by-Nuvation-Bio-Inc.html
12 Jun 2025
// REUTERS
https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-approves-nuvation-bios-lung-cancer-therapy-2025-06-11/
21 May 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250521881222/en/Nuvation-Bio-To-Present-New-Data-from-Pivotal-Clinical-Studies-of-Taletrectinib-in-Advanced-ROS1-Positive-Non-Small-Cell-Lung-Cancer-at-ASCO-2025-Annual-Meeting
13 May 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250513735131/en/Nuvation-Bio-to-Present-Matching-adjusted-Indirect-Comparison-Data-for-Taletrectinib-vs.-Entrectinib-at-ISPOR-2025
25 Mar 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250325813594/en/Nuvation-Bio-to-Present-New-Nonclinical-Data-for-Taletrectinib-at-the-American-Association-for-Cancer-Research-Annual-Meeting-2025
Share 